Allurion Exercises 2.66M Warrants at $1.15 to Raise $3M
Allurion Technologies will immediately exercise 2.66 million warrants at $1.15 per share, raising $3 million with closing expected on Feb. 25. It plans to register up to 5.32 million shares underlying new warrants and has filed a premarket approval application with U.S. regulators for its Allurion Gastric Balloon System.
1. Warrant Exercise and Proceeds
Allurion Technologies entered into a definitive agreement to exercise 2.66 million outstanding warrants at $1.15 per share, generating approximately $3 million in gross proceeds. The transaction is set to close on or around Feb. 25, bolstering the company’s cash position.
2. Resale Registration and Dilution Implications
As part of the deal, Allurion agreed to file a resale registration statement covering up to 5.32 million shares underlying new warrants issued in a private placement. This move raises potential dilution, increasing the total share count if all warrants are exercised.
3. FDA PMA Application for Gastric Balloon
On Feb. 23, Allurion filed a premarket approval application with U.S. regulators for its Allurion Gastric Balloon System featuring the Allurion Smart Capsule. The device is positioned as a non-surgical obesity treatment alternative to GLP-1 therapy and bariatric surgery.
4. Market Reaction and Outlook
Shares fell 6.25% following the warrant announcement and are trading 8.5% below their 20-day moving average and 12.3% below their 100-day moving average. The stock has declined 68% over the past year; analysts maintain a buy rating with an average target of $48.50, and next earnings are scheduled for March 25, 2026.